CXA-201

· Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CXA-201, covering 2015-01-15 to 2015-01-15. Get the full timeline:

Most recent: Clinical Trial Update: Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections [Phase 3]

See pricing